SUPPLEMENTAL MATERIAL

Supplemental Figure S1. Confirmation of bone marrow engraftment. Representative flow plots showing the percentage of engraftment for CD45.1 and CD45.2 leukocytes, two months after bone marrow transplantation in radiated mice.



Supplemental Figure S2. Apoptosis induction in Jurkat T cells with 0.1 μM camptothecin.

Representative flow plots showing Jurkat T-cells before (left panel) and after 16 hours of 0.1 μM camptothecin treatment (right panel) using Viobility and Annexin A5 markers.



Supplemental Figure S3. End-diastolic and end-systolic volume 1 day post-MI. (A) End-diastolic and (B) end-systolic volumes measured normalized for body weight in male mice 1 day post-MI as measured by MRI. n = 17-18 mice per genotype. Data are presented as mean ± SEM.



Supplemental Figure S4. Infarct size and cardiac function changes during 21 days post-MI period. (A) Myocardial infarct size, (B) ejection fraction, (C) end-diastolic volume and (D) end-systolic volume in WT and *Nlrp3*$^{-/-}$ female mice measured by MRI and normalized for body weight 1, 7 and 21 days post-MI. n= 7-13 mice per group. To avoid underrepresentation of the data, due to drop out of mice during the time course of the study, t-tests are used instead of a repeated measures ANOVA. Data are presented as mean ± SEM. *p<0.05, **p<0.01.



Supplemental Figure S5. *Nlrp3*$^{-/-}$ mice have altered myocardial levels of neutrophils 3 days post-MI. Percentage of Ly6G (A and B) and Mac2 (C and D) positive cells per indicated area of the left ventricle in WT and *Nlrp3*$^{-/-}$ mice 1 and 3 days post-MI. Representative cross sections for Ly6G and Mac2 staining (scale bars are 200 µM) are shown next to the corresponding bar graph (Sham; n=3, Viable LV and MI; Ly6G; Day 1 post MI; n=12 WT, n=13 *Nlrp3*$^{-/-}$. Day 3 post MI; n=8 WT, n=7 *Nlrp3*$^{-/-}$. Mac2; Day 1 post MI; n=11 WT, n=15 *Nlrp3*$^{-/-}$, Day 3 post MI; n=9 WT, n=6 *Nlrp3*$^{-/-}$). Data are presented as mean ± SEM. *p< 0.05



ABBREVIATIONS IN FIGURE 3

Afp = alpha fetoprotein

Ahsg = alpha-2-HS-glycoprotein

Alb = albumin

Apoh = apolipoprotein H

Cd109 = CD109 antigen

Cd40 = CD40 antigen

Col6a5 = collagen, type VI, alpha 5

Cx3cl1 = chemokine (C-X3-C motif) ligand 1

Ecm1 = extracellular matrix protein 1

Egfr = epidermal growth factor receptor

Egln1 = egl-9 family hypoxia-inducible factor 1

Emilin1 = elastin microfibril interfacer 1

Emilin2 = elastin microfibril interfacer 2

F10 = coagulation factor X

F11r = F11 receptor

F12 = coagulation factor XII (Hageman factor)

F9 = coagulation factor IX

Fbln2 = fibulin 2

Fbln5 = fibulin 5

Fbn1 = fibrillin 1

Fgb = fibrinogen beta chain

Fos = FBJ osteosarcoma oncogene

Fstl1 = follistatin-like 1

Gp1bb = glycoprotein Ib, beta polypeptide

Grn = granulin

Hgs = HGF-regulated tyrosine kinase substrate

Igfbp4 = insulin-like growth factor binding protein 4

Igfbp5 = insulin-like growth factor binding protein 5

Igfbp6 = insulin-like growth factor binding protein 6

Igfbp7 = insulin-like growth factor binding protein 7

Lamb1 = laminin B1

Lamp1 = lysosomal-associated membrane protein 1

Lamp2 = lysosomal-associated membrane protein 2

Ltbp2 = latent transforming growth factor beta binding protein 2

M6pr = mannose-6-phosphate receptor, cation dependent

Mfap5 = microfibrillar associated protein 5

Pdcl3 = phosducin-like 3

Plg = plasminogen

Proz = protein Z, vitamin K-dependent plasma glycoprotein

Psap = prosaposin

Pxdn = peroxidasin

Pxn = paxillin

Sash1 = SAM and SH3 domain containing 1

Selenop = selenoprotein P

Sparc = secreted acidic cysteine rich glycoprotein

Sparcl1 = SPARC-like 1

Tgfb1i1 = transforming growth factor beta 1 induced transcript 1

Thbd = thrombomodulin

Timp1 = tissue inhibitor of metalloproteinase 1

Tnc = tenascin C

Twsg1 = twisted gastrulation BMP signaling modulator 1

Vegfa = vascular endothelial growth factor A

Vwf = Von Willebrand factor